Sign Up for Alerts
Sign up to receive receive industry-specific emails from our legal team.
Sign Up for Alerts
We provide tailored, industry-specific legal updates to our clients and other friends of the firm.
Areas of Interest
November 12th, 2022
How an Ad Tech Firm Co-opted IAB Europe’s Transparency and Consent Framework to Collect Fingerprinting Data
Privacy & Data Security Chair Daniel M. Goldberg is quoted in the article, “How an Ad Tech Firm Co-opted IAB Europe’s Transparency and Consent Framework to Collect Fingerprinting Data” published by Digiday. The article discusses Confiant, the ad security monitoring company that detected an ad tech company exploiting the framework to collect information on people in the U.S. Daniel is quoted saying, “The brand is responsible for any type of tracking technology that is on its site. The brand is the gatekeeper. So Voldrakus somehow or another is able to get data from the site, and so under the law, very technically speaking, the brand could be held liable for the data that is collected and pass[ed] to Voldrakus.”
Read the full article here.
Other Quoted
Climate Diaries Cannes Lions 2026
Jeffrey A. Greenbaum is featured in the 51toCarbonZero article, Climate Diaries Cannes Lions 2026, which features eleven interviews with senior leaders from across the media and advertising industry conducted at the Cannes Lions International Festival of Creativity. Read more.
August 5 2026
‘I have been hunted down by HR reps, lawyers, and comms people:’ Developers discuss the pain and prevalence of side work clauses
Wendy Stryker was quoted in a Game Developer article discussing "side work clauses," also known as "moonlighting clauses," in video game industry employment contracts. Read more.
July 30 2026
Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads
Jeffrey A. Greenbaum was quoted in the Regulatory Affairs Professionals Society (RAPS) article, "Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads." The article discusses the FDA's proposal to eliminate the "adequate provision" requirement in direct-to-consumer (DTC) prescription drug advertising, a change that experts say could effectively result in a de facto ban on prescription drug advertisements. Read more.
July 21 2026
